Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Mitchell G. Miglis*, Charles H. Adler, Elena Antelmi, Dario Arnaldi, Luca Baldelli, Bradley F. Boeve, Matteo Cesari, Irene Dall'Antonia, Nico J. Diederich, Kathrin Doppler, Petr Dušek, Raffaele Ferri, Jean François Gagnon, Ziv Gan-Or, Wiebke Hermann, Birgit Högl, Michele T. Hu, Alex Iranzo, Annette Janzen, Anastasia KuzkinaJee-Young Lee, Klaus L. Leenders, Simon J. G. Lewis, Claudio Liguori, Jun Liu, Christine Lo, Kaylena A. Ehgoetz Martens, Jiri Nepozitek, Giuseppe Plazzi, Federica Provini, Monica Puligheddu, Michal Rolinski, Jan Rusz, Ambra Stefani, Rebekah L. S. Summers, Dallah Yoo, Jennifer Zitser, Wolfgang H. Oertel

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

121 Citations (Scopus)

Abstract

Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal α-synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades. These findings provide the rationale to develop reliable biomarkers that can better predict conversion to clinically manifest α-synucleinopathies. In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of α-synucleinopathy patients with isolated RBD might develop.

Original languageEnglish
Pages (from-to)671-684
Number of pages14
JournalThe Lancet Neurology
Volume20
Issue number8
DOIs
Publication statusPublished - Aug 2021
Externally publishedYes

Fingerprint

Dive into the research topics of 'Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder'. Together they form a unique fingerprint.

Cite this